CLINIC, DIFFERENTIAL DIAGNOSIS AND TREATMENT OF GALACTOSEMIA
Abstract
Key words: children, galactosemia, treatment, screening.
About the Authors
N.V. ZhurkovaRussian Federation
O.B. Kondakova
Russian Federation
T.V. Bushueva
Russian Federation
E.P. Rybakova
Russian Federation
T.E. Borovik
Russian Federation
References
1. Захарова Е.Ю., Воскобоева Е.Ю., Байдакова Г.В. Галактоземия, тип 1: клинические проявления, диагностика и лечение. В кн.: Молекулярно–биологические технологии в медицинской практике. Новосибирск: Альфа Виста. 2006. С. 155–160.
2. Новиков В.П., Ходунова А.А., Денисова С.Н. Галактоземия у детей: распространенность, клинико-генетическая гетерогенность, способы диагностики и лечения. Вопросы детской диетологии. 2006; 4 (6): 53–65.
3. Antshel K., Epstein I., Waisbren S.Cognitive strengths and weaknesses in children and adolescents homozygous for the galactosemia Q188R mutation: a descriptive study. Neuropsychology. 2004; 18 (4): 658–664.
4. Arn P. Galactosemia. Curr. Treat. Options. Neurol. 2003; 5 (4): 343–345.
5. Bosch A. Classical galactosaemia revisited. J. Inherit. Metab. Dis. 2000; 11: 434–440.
6. Bosch A., Bakker H., van Gennip A. et al. Clinical features of galactokinase deficiency: a review of the literature. J. Inherit. Metab. Dis. 2002; 25 (8): 6299634.
7. Garden A., Davidson D. Recommendations for the management of galactosaemia. Arch. Dis. Child. 2000; 82 (3): 266.
8. Holton J., Walter J., Tyfield L. et al. The Metabolic and Molecular Bases of Inherited Disease New York: McGraw–Hill. 2001. Vol. II. P. 2297–2326.
9. Hunter M., Heyer E., Austerlitz F. The P28T mutation in the GALK1 gene accounts for galactokinase deficiency in Roma (Gypsy) patients across Europe. Pediatr. Res. 2002; 51 (5): 602–606.
10. Maceratesi P., Daude N., Dallapiccola B. et al. Human UDP9galactose 49prime epimerase (GALE) gene and identification of five missense mutations in patients with epimerase9deficiency galactosemia. Molec. Genet. Metab. 1998; 51: 602–606.
11. Misumi H., Wada H., Kawakami M. et al. Detection of UDP9 galactose 4 epimerase deficiency in a galactosemia screening program. Clin. Chim. Acta. 1981; 116 (1): 101–105.
12. Openo K.K., Schulz J.M., Vargas C.A. et al. Epimerase9deficiency galactosemia is not a binary condition. Am. J. Hum. Genet. 2006; 68: 89–102.
13. Reich S., Hennerman J., Vetter B. An unexpectedly high frequency of hypergalactosemia in an immigrant Bosnian population revealed by newborn screening. Pediatr. Res. 2002; 51: 598–601.
14. Ridel K., Leslie N., Gilbert D. An updated review of the long term neurological effects of galactosemia. Pediatr. Neurol. 2005; 33 (3): 153–161.
15. Sangiuolo F., Magnani M., Stambolian D. Biochemical characterization of two GALK1 mutations in patients with galactokinase deficiency. Hum. Mutat. 2004; 23: 396.
16. Thoden J., Wohlers T., Fridovich9Keil J. et al. Molecular basis for severe epimerase deficiency galactosemia: x-ray structure of the human V94M9substituted UDP galactose 4 epimerase. J. Biol. Chem. 2001; 276: 20617–20623.
Review
For citations:
Zhurkova N., Kondakova O., Bushueva T., Rybakova E., Borovik T. CLINIC, DIFFERENTIAL DIAGNOSIS AND TREATMENT OF GALACTOSEMIA. Current Pediatrics. 2008;7(5):71-74.
Email this article 
